AR1001 met the primary endpoint in the prespecified Monotherapy population, with a CDR-SB treatment difference of -0.44 points versus placebo at Week 52 (p...
Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed I...
The FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) submissions for etavopivat are based on da...
ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor ago...
An Australian-developed therapy aimed at halting the progression of motor neurone disease (MND) and restoring function by supporting the repair o...
Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase...
94% of participants maintained seroresponse five years after a single vaccination Comparable antibody persistence observed in older (65+) and younger adul...
Comprehensive clinical and scientific data supporting Phase 2 development of nangibotide in ACLF unveiled to leading experts during AASLD The Liver Meeting...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced positive results from two Phase 2 trials of Shigella4V2 (S4V2), the ...
The completed Phase 1a study data in healthy volunteers showed early signs of pharmacodynamic activity supporting further clinical evaluation of RES-010 T...
40-fold lower virus load compared to placebo on Day 2, at the peak of viral replication Exposure-response relationship observed, with greater interferon l...
Findings build on TJ Biopharma's pioneering work on GM-CSF as a therapeutic target in macrophage- and myeloid cell-driven inflammation Phase 2 results s...
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) announces that regulatory filings for ORPATHYS® (savolitinib) in combinati...
Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrat...
© 2026 Biopharma Boardroom. All Rights Reserved.